MXC secures interim GMP certification for European facility
MGC Pharmaceuticals (ASX:MXC) announced today that it has attained interim Good Manufacturing Practice (GMP) for its recently completed European medicinal cannabis production facility.
The interim certification is one of the final steps towards full GMP certification, with the latter allowing MXC to distribute its CannEpilTM product as well as other pharmaceutical-grade medicinal cannabis products.
The interim certification will pave the way for MXC to commence production of its first batch of CannePilTM. Upon completion of the first batch, the product will undergo validation of manufacturing and rigorous analysis before being approved for wider production.
CanneEpilTM is MXC’s first medicinal cannabis offering, which targets drug resistant epilepsy, also known as refractory epilepsy. Refractory epilepsy affects 30 per cent of the estimated 240,000 people diagnosed with epilepsy in Australia annually.
The company has partnered with Australian pharmaceutical distributor, HL Pharma Pty Ltd, to bring CannePilTM to the Australian market. Under the agreement, HL Pharma is responsible for ensuring Therapeutic Goods Administration (TGA) and Office of Drug Control approval to import and supply the products in Australia.
It’s worth noting here that this is an early stage play and investors should seek professional financial advice if considering this company for their portfolio.
A step closer to revenues
Upon Australian regulatory approval, CannEpilTM is projected to generate approximately A$1 million per annum in its first full year of distribution. Projected revenue is modelled on less than 100 current patients registered through MXC’s relationship with Epilepsy Action Australia.
The company also indicated that full GMP certification for its extraction facility remains on schedule, with the expected certification to place MXC in an advantageous position to capitalise on key markets in Europe, North America and Australasia.
Co-founder and CEO of MXC, Roby Zomer, commented on the promising update.
“MGC has a vision and defined strategy of becoming a leading pharmaceutical-grade medicinal cannabis company and the receipt of GMP certification for our European manufacturing facility is a key milestone in this journey.
“Once we receive full certification, we will be positioned to rapidly progress our operations in Europe with a core focus on medical research and development of the company’s pharmaceutical products pipeline,” Zomer said.
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.